Alk-Abelló A/O
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.
Allergic Rhinitis Due to House Dust Mite
Allergic asthma due to dermatophagoides
Allergic Asthma Due to Dermatophagoides Pteronyssinus
Tablet, Dispersible
Condition: * persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication * HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 1508 participants |
| Official Title : | Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX® 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France |
| Actual Study Start Date : | 2018-05-09 |
| Estimated Primary Completion Date : | 2020-09-29 |
| Estimated Study Completion Date : | 2020-09-29 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 65 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Arnaud de Villeneuve Hospital
Montpellier, France, 34090